Ring, chief legal officer, sells Nurix (NRIX) shares for $125,792
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends surge on wider Middle East conflict, Strait of Hormuz closure Dollar surges to over five-week high on U.S.-Iran escalation; euro, sterling slip Gold prices climb amid boost to safe haven demand after U.S.-Iran escalation Gold price surge after Iran attack could fade, Pepperstone says FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Ring, chief legal officer, sells Nurix shares for $125,792 By Investing.com Insider Trading Published 03/02/2026, 11:13 PM Ring, chief legal officer, sells Nurix shares for $125,792 0 NRIX -1.00% Christine Ring, Chief Legal Officer of Nurix Therapeutics NASDAQ:NRIX, sold 8,148 shares of common stock on March 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $15.4385, resulting in a total transaction value of $125,792. The sale comes as NRIX stock has surged 67% over the past six months, though it remains down 17% year-to-date. The price per share in the sale ranged from a low of $15.16 to a high of $15.845. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Ring directly owns 34,601 shares of Nurix Therapeutics.According to InvestingPro analysis, the stock appears undervalued at current levels. For deeper insights into NRIX’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities. In other recent news, Nurix has been the subject of several analyst updates following its fourth-quarter fiscal 2025 financial results. The company reported a net loss of $0.82 per share, which was slightly better than the $0.84 per share loss estimated by H.C. Wainwright, leading the firm to raise its price target to $32 while maintaining a Buy rating. Piper Sandler also adjusted its price target to $35, citing accelerated development plans for Nurix’s bexobrutideg treatmen...
Read full article at source